Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Mass Balance of TAK-831 (Luvadaxistat) in Healthy Men
NCT04234672Phase 1Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Feb 2020
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of luvadaxistat in schizophrenia and Friedreich ataxia (FA), sponsored by Neurocrine Biosciences. Primary endpoints: Percent Absolute Bioavailability (%F) for TAK-831 at Day 1, Total Radioactivity Expressed as Cumulative Percentage of Dose Eliminated in Urine and Feces Combined up to 240 hours and 5 more. Started Feb 2020; status: completed.
02
Drugs
luvadaxistat
03
Conditions
schizophreniaFriedreich ataxia (FA)
Beyond the preview
Go deeper on NCT04234672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04234672.